Year archive

Lineage Cell Therapeutics Inc. — 2024 filings

All 156 regulatory filings released by Lineage Cell Therapeutics Inc. (LCTX) in 2024, sourced directly from the official regulator.

156 Filings

2024 Period

2024 filings (156)

Filing	Released	Lang
DEF 14A Proxy Solicitation & Information Statement	2024-12-09	English
PRE 14A Regulatory Filings	2024-11-29	English
4 Director's Dealing	2024-11-26	English
4 Director's Dealing	2024-11-26	English
FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP- Mulroy Michael H Director's Dealing	2024-11-26	English
FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP- Mulroy Michael H Director's Dealing	2024-11-26	English
4 Director's Dealing	2024-11-25	English
FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP - Culley Brian M Director's Dealing	2024-11-25	English
FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP - Culley Brian M Director's Dealing	2024-11-25	English
SCHEDULE 13D/A -Broadwood, Neal C. Bradsher Major Shareholding Notification	2024-11-24	English
SCHEDULE 13D/A -Broadwood, Neal C. Bradsher Regulatory Filings	2024-11-24	English
Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering Share Issue/Capital Change	2024-11-24	English
Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering Capital/Financing Update	2024-11-24	English
Prospectus disclosing information, facts, events covered in form 424B5 Capital/Financing Update	2024-11-24	English
Prospectus disclosing information, facts, events covered in form 424B5 Capital/Financing Update	2024-11-24	English
Lineage entered into securities purchase agreements relating to the purchase and sale of common shares and warrants Regulatory Filings	2024-11-24	English
Lineage entered into securities purchase agreements relating to the purchase and sale of common shares and warrants Capital/Financing Update	2024-11-24	English
4 Director's Dealing	2024-11-22	English
Major Shareholding Notification 2024 Major Shareholding Notification	2024-11-22	English
424B5 Regulatory Filings	2024-11-21	English
8-K Regulatory Filings	2024-11-20	English
Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering Capital/Financing Update	2024-11-20	English
Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering Capital/Financing Update	2024-11-20	English
Quarterly report which provides a continuing view of a company's financial position Interim / Quarterly Report 9M 2024	2024-11-17	English
Quarterly report which provides a continuing view of a company's financial position Report Publication Announcement	2024-11-17	English
Third Quarter 2024 Financial Results and Provides Business Update Earnings Release Q3 2024	2024-11-17	English
Third Quarter 2024 Financial Results and Provides Business Update Earnings Release Q3 2024	2024-11-17	English
10-Q Interim / Quarterly Report Q3 2024	2024-11-14	English
8-K Regulatory Filings	2024-11-14	English
to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024 Earnings Release Q3 2024	2024-11-10	English
to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024 Report Publication Announcement	2024-11-10	English
Major Shareholding Notification 2024 Major Shareholding Notification	2024-11-08	English
Major Shareholding Notification 2024 Major Shareholding Notification	2024-10-22	English
4 Director's Dealing	2024-08-20	English
FORM10-Q-Quarterly report which provides a continuing view of a company's financial position Interim / Quarterly Report H1 2024	2024-08-11	English
FORM10-Q-Quarterly report which provides a continuing view of a company's financial position Report Publication Announcement Q2 2024	2024-08-11	English
Second Quarter 2024 Financial Results and Provides Business Update Earnings Release Q2 2024	2024-08-11	English
Second Quarter 2024 Financial Results and Provides Business Update Earnings Release Q2 2024	2024-08-11	English
10-Q Interim / Quarterly Report Q2 2024	2024-08-08	English
8-K Regulatory Filings	2024-08-08	English
4 Director's Dealing	2024-07-03	English
4 Director's Dealing	2024-07-03	English
4 Director's Dealing	2024-07-03	English
4 Director's Dealing	2024-07-03	English
4 Director's Dealing	2024-07-03	English
4 Director's Dealing	2024-07-03	English
Director's Dealing 2024 Director's Dealing	2024-07-03	English
Changes in Registrant’s Certifying Accountant Regulatory Filings	2024-06-17	English
Changes in Registrant’s Certifying Accountant Regulatory Filings	2024-06-17	English
Amendments to Articles of Incorporation or Bylaws; Submission of Matters to a Vote of Security Holder Regulatory Filings	2024-06-17	English
Amendments to Articles of Incorporation or Bylaws; Submission of Matters to a Vote of Security Holder Report Publication Announcement	2024-06-17	English
8-K Regulatory Filings	2024-06-14	English
8-K Regulatory Filings	2024-06-13	English
to Present at 2024 BIO International Convention Regulatory Filings	2024-06-02	English
to Present at 2024 BIO International Convention Report Publication Announcement	2024-06-02	English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-CULLEY BRAIN M Director's Dealing	2024-05-29	English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-CULLEY BRAIN M Director's Dealing	2024-05-29	English
4 Director's Dealing	2024-05-28	English
Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium Earnings Release Q2 2024	2024-05-21	English
Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium Regulatory Filings	2024-05-21	English
opinion of Sheppard Mullin Richter & Hampton, LLP relating to the legality of the ATM Shares Regulatory Filings	2024-05-21	English
opinion of Sheppard Mullin Richter & Hampton, LLP relating to the legality of the ATM Shares Report Publication Announcement	2024-05-21	English
prospectus disclosing information, facts, events Capital/Financing Update	2024-05-21	English
prospectus disclosing information, facts, events Regulatory Filings	2024-05-21	English
Regulatory Filings 2024 Regulatory Filings	2024-05-15	English
8-K Regulatory Filings	2024-05-14	English
424B5 Regulatory Filings	2024-05-14	English
Quarterly report which provides a continuing view of a company's financial position Interim / Quarterly Report Q1 2024	2024-05-11	English
Quarterly report which provides a continuing view of a company's financial position Report Publication Announcement Q1 2024	2024-05-11	English
First Quarter 2024 Financial Results and Provides Business Update Earnings Release Q1 2024	2024-05-11	English
First Quarter 2024 Financial Results and Provides Business Update Earnings Release Q1 2024	2024-05-11	English
10-Q Interim / Quarterly Report Q1 2024	2024-05-09	English
8-K Regulatory Filings	2024-05-09	English
OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit Earnings Release Q2 2024	2024-05-06	English
OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit Report Publication Announcement	2024-05-06	English
Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024 Earnings Release Q1 2024	2024-05-05	English
Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024 Report Publication Announcement	2024-05-05	English
Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM) Regulatory Filings	2024-04-30	English
Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM) Report Publication Announcement	2024-04-30	English
FORM 10-K-Form ARS - An annual report to security holders Annual Report FY 2023	2024-04-30	English
FORM 10-K-Form ARS - An annual report to security holders Report Publication Announcement	2024-04-30	English
Additional proxy soliciting materials - definitive Proxy Solicitation & Information Statement	2024-04-30	English
Additional proxy soliciting materials - definitive Remuneration Information	2024-04-30	English
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 11, 2024, PROXY Proxy Solicitation & Information Statement	2024-04-30	English
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 11, 2024, PROXY AGM Information	2024-04-30	English
Changes to Board of Directors Board/Management Information	2024-04-30	English
Changes to Board of Directors Board/Management Information	2024-04-30	English
ARS Annual Report	2024-04-29	English
DEFA14A Regulatory Filings	2024-04-29	English
DEF 14A Proxy Solicitation & Information Statement	2024-04-29	English
ROSPECTUS SUPPLEMENT (To prospectus dated March 19, 2021) -sale agreement with B.Riley to sale of our common shares offers up to 40M$ Capital/Financing Update	2024-03-24	English
ROSPECTUS SUPPLEMENT (To prospectus dated March 19, 2021) -sale agreement with B.Riley to sale of our common shares offers up to 40M$ Report Publication Announcement	2024-03-24	English
Entry into a Material Definitive Agreement & Other Events Regulatory Filings	2024-03-24	English
Entry into a Material Definitive Agreement & Other Events Report Publication Announcement	2024-03-24	English
Regulatory Filings 2024 Regulatory Filings	2024-03-22	English
8-K Regulatory Filings	2024-03-22	English
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium Regulatory Filings	2024-03-18	English
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium Regulatory Filings	2024-03-18	English
RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit Regulatory Filings	2024-03-13	English
RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit Regulatory Filings	2024-03-13	English
RG6501 (OPREGEN®) PRECLINICAL ENGRAFTMENT RESULTS TO BE PRESENTED AT 2024 ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY MEETING Regulatory Filings	2024-03-11	English
RG6501 (OPREGEN®) PRECLINICAL ENGRAFTMENT RESULTS TO BE PRESENTED AT 2024 ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY MEETING Report Publication Announcement	2024-03-11	English
FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Samuel George A. III Director's Dealing	2024-03-10	English
FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Samuel George A. III Director's Dealing	2024-03-10	English
FORM S-3-Registration Statements Transaction in Own Shares	2024-03-10	English
FORM S-3-Registration Statements Report Publication Announcement	2024-03-10	English
FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Howe Jill Ann Director's Dealing	2024-03-10	English
FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Howe Jill Ann Major Shareholding Notification	2024-03-10	English
FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP- Culley Brian M Director's Dealing	2024-03-10	English
FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP- Culley Brian M Director's Dealing	2024-03-10	English
Annual report which provides a comprehensive overview of the company for the past year Annual Report FY 2023	2024-03-10	English
Annual report which provides a comprehensive overview of the company for the past year Report Publication Announcement	2024-03-10	English
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Earnings Release Q4 2023	2024-03-10	English
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Report Publication Announcement	2024-03-10	English
Director's Dealing 2024 Director's Dealing	2024-03-08	English
Director's Dealing 2024 Director's Dealing	2024-03-08	English
Director's Dealing 2024 Director's Dealing	2024-03-08	English
Regulatory Filings 2024 Regulatory Filings	2024-03-07	English
10-K Annual Report FY 2023	2024-03-07	English
8-K Regulatory Filings	2024-03-07	English
to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024 Earnings Release Q4 2023	2024-02-29	English
to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024 Report Publication Announcement	2024-02-29	English
Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury Regulatory Filings	2024-02-18	English
Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury Regulatory Filings	2024-02-18	English
The 2024 annual meeting of shareholders is scheduled to be held on June 11,2024 Regulatory Filings	2024-02-18	English
The 2024 annual meeting of shareholders is scheduled to be held on June 11,2024 AGM Information	2024-02-18	English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Culley Brian M Director's Dealing	2024-02-18	English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Culley Brian M Director's Dealing	2024-02-18	English
Regulatory Filings 2024 Regulatory Filings	2024-02-15	English
Director's Dealing 2024 Director's Dealing	2024-02-13	English
Director's Dealing 2024 Director's Dealing	2024-02-13	English
ANNOUNCES CLOSING OF $14.0 MILLION REGISTERED DIRECT OFFERING Capital/Financing Update	2024-02-11	English
ANNOUNCES CLOSING OF $14.0 MILLION REGISTERED DIRECT OFFERING Capital/Financing Update	2024-02-11	English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-BAILEY DON M Director's Dealing	2024-02-11	English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-BAILEY DON M Director's Dealing	2024-02-11	English
Schedule 13D - Broadwood Partners, L.P Major Shareholding Notification	2024-02-11	English
Schedule 13D - Broadwood Partners, L.P Regulatory Filings	2024-02-11	English
FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-BROADWOOD PARTNERS LP Director's Dealing	2024-02-11	English
FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-BROADWOOD PARTNERS LP Director's Dealing	2024-02-11	English
Director's Dealing 2024 Director's Dealing	2024-02-09	English
Director's Dealing 2024 Director's Dealing	2024-02-09	English
Major Shareholding Notification 2024 Major Shareholding Notification	2024-02-09	English
Entry into a Material Definitive Agreement; Other Events; Regulatory Filings	2024-02-06	English
Entry into a Material Definitive Agreement; Other Events; Regulatory Filings	2024-02-06	English
PROSPECTUS SUPPLEMENT (To prospectus dated March 19, 2021) Share Issue/Capital Change	2024-02-06	English
PROSPECTUS SUPPLEMENT (To prospectus dated March 19, 2021) Regulatory Filings	2024-02-06	English
PROSPECTUS SUPPLEMENT (To prospectus dated March 19, 2021 and prospectus supplements dated May 18, 2023 and December 21, 2021) Share Issue/Capital Change	2024-02-06	English
PROSPECTUS SUPPLEMENT (To prospectus dated March 19, 2021 and prospectus supplements dated May 18, 2023 and December 21, 2021) Capital/Financing Update	2024-02-06	English
Regulatory Filings 2024 Regulatory Filings	2024-02-06	English
Regulatory Filings 2024 Regulatory Filings	2024-02-06	English
Regulatory Filings 2024 Regulatory Filings	2024-02-06	English
RG6501 (OpRegen®) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Exudation and Degeneration Meeting in Presentation by Allen Ho, MD, FACS, FASRS Regulatory Filings	2024-01-23	English
RG6501 (OpRegen®) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Exudation and Degeneration Meeting in Presentation by Allen Ho, MD, FACS, FASRS Regulatory Filings	2024-01-23	English
Form 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP - Jayasuriya Anula Director's Dealing	2024-01-08	English
Form 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP - Jayasuriya Anula Director's Dealing	2024-01-08	English
Director's Dealing 2024 Director's Dealing	2024-01-03	English

Filings by year

2026 38 filings
2025 67 filings
2024 156 filings
2023 121 filings
2022 190 filings
2021 273 filings
2020 185 filings
2019 269 filings
2018 215 filings
2017 354 filings
2016 227 filings
2015 186 filings
2014 116 filings
2013 125 filings
2012 95 filings
2011 63 filings
2010 97 filings